A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder

Johnson & Johnson (J&J)

Status and phase

Completed

Phase 2

Conditions

Major Depressive Disorder

Treatments

Drug: Placebo and Paroxetine

Drug: R228060

Study type

Interventional

Funder types

Industry

Identifiers

NCT00073203

CR004339

Details and patient eligibility

About

The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder.

Approximately 488 subjects will be involved in the study.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Generally healthy adults on the basis of a physical examination, medical history, ECG and laboratory work-up.
Subject needs to meet criteria for diagnosis of moderate or severe major depression as defined by the protocol.
The subject also needs to be an outpatient to participate in this study.